
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39237579
71739
10.1038/s41598-024-71739-y
Article
IGF-I concentration determines cell fate by converting signaling dynamics as a bifurcation parameter in L6 myoblasts
Okino Ryosuke 16
Mukai Kazuaki 1
Oguri Shunpei 1
Masuda Masato 12
Watanabe Satoshi 3
Yoneyama Yosuke 14
Nagaosa Sumine 1
Miyamoto Takafumi 789
Mochizuki Atsushi 5
Takahashi Shin-Ichiro 1
Hakuno Fumihiko hakuno@g.ecc.u-tokyo.ac.jp

1
1 https://ror.org/057zh3y96 grid.26999.3d 0000 0001 2169 1048 Department of Animal Resource Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan
2 https://ror.org/059d6yn51 grid.265125.7 0000 0004 1762 8507 Faculty of Information Sciences and Arts, Toyo University, Saitama, Japan
3 grid.69566.3a 0000 0001 2248 6943 Advanced Institute for Materials Research, Tohoku University, Sendai, Japan
4 https://ror.org/051k3eh31 grid.265073.5 0000 0001 1014 9130 Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan
5 https://ror.org/02kpeqv85 grid.258799.8 0000 0004 0372 2033 Laboratory of Mathematical Biology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan
6 Muscle Biology Laboratory, Research Team for Aging Science, Tokyo Metropolitan Institute for Geriatric and Gerontology (TMIG), Tokyo, Japan
7 https://ror.org/02956yf07 grid.20515.33 0000 0001 2369 4728 Department of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba, Ibaraki, Japan
8 https://ror.org/02956yf07 grid.20515.33 0000 0001 2369 4728 Transborder Medical Research Center, University of Tsukuba, Ibaraki, Japan
9 https://ror.org/02956yf07 grid.20515.33 0000 0001 2369 4728 Cybermedicine Research Center, University of Tsukuba, Ibaraki, Japan
5 9 2024
5 9 2024
2024
14 206991 2 2024
30 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Insulin-like growth factor (IGF)-I mediates long-term activities that determine cell fate, including cell proliferation and differentiation. This study aimed to characterize the mechanisms by which IGF-I determines cell fate from the aspect of IGF-I signaling dynamics. In L6 myoblasts, myogenic differentiation proceeded under low IGF-I levels, whereas proliferation was enhanced under high levels. Mathematical and experimental analyses revealed that IGF-I signaling oscillated at low IGF-I levels but remained constant at high levels, suggesting that differences in IGF-I signaling dynamics determine cell fate. We previously reported that differential insulin receptor substrate (IRS)-1 levels generate a driving force for cell competition. Computational simulations and immunofluorescence analyses revealed that asynchronous IRS-1 protein oscillations were synchronized during myogenic processes through cell competition. Disturbances of cell competition impaired signaling synchronization and cell fusion, indicating that synchronization of IGF-I signaling oscillation is critical for myoblast cell fusion to form multinucleate myotubes.

Keywords

Insulin-like growth factor-I
Signaling dynamics
Signaling oscillation
Cell competition
L6 myoblast
Myogenesis
Bifurcation analysis
Subject terms

Cellular signalling networks
Growth factor signalling
http://dx.doi.org/10.13039/501100001691 Japan Society for the Promotion of Science B24380152 B15H04583 B22H02528 A16208028 A22248030 S25221204 Takahashi Shin-Ichiro Hakuno Fumihiko http://dx.doi.org/10.13039/501100007173 Bio-oriented Technology Research Advancement Institution Cross-ministerial Moonshot Agriculture, Forestry, and Fisheries Research and Development Program, “Technologies for Smart Bio-industry and Agriculture,” Takahashi Shin-Ichiro issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Insulin-like growth factor-I (IGF-I) is an anabolic hormone with a structure similar to proinsulin1. Insulin mediates acute metabolic functions, including glucose uptake in skeletal muscles and adipose tissues, whereas IGF-I mediates long-term actions that determine cell fate, including cell growth, differentiation, and cell survival2. However, it is unclear how IGF-I promotes cell proliferation and differentiation, which appear to have opposite bioactivities.

Skeletal muscle development is mediated by stem cells called satellite cells. Satellite cells proliferate and activate into myoblasts in response to physical stimuli or growth signaling3. IGF-I is essential for promoting satellite cell proliferation and activation into myoblasts4–6. Owing to this activity, muscle-specific IGF-I transgenic mice showed myofiber hypertrophy7. Contrarily, IGF-I receptor null mutant mice showed decreased muscle mass8. In the rat L6 myoblast cell line, IGF-I has also been shown to play critical roles in both myoblast differentiation and proliferation9–12. IGF-I stimulation induces cell growth13, and in the absence of IGF-I, myogenic differentiation into myotubes does not occur. Moreover, adding an inhibitor of the p85 phosphatidylinositol 3-kinase (PI3K), one of the main IGF-I signaling pathways blocks both IGF-I-induced proliferation and differentiation14. Thus, the IGF-I hormone and its signaling activity are essential for both muscle proliferation and differentiation. Florini et al. showed a biphasic relationship between the concentration of IGF-I and the differentiation of L6 myoblasts. Muscle differentiation was not induced without IGF-I but inhibited at high concentrations15. However, the differences in IGF-I signaling activity during muscle differentiation and proliferation are unknown.

Generally, after binding to specific receptors on the plasma membrane, IGF-I activates its intrinsic tyrosine kinase activity16,17. The activated receptors phosphorylate several intracellular substrates, including insulin receptor substrates (IRSs)18. Tyrosine phosphorylation of IRSs leads to their binding to several intermediate signaling molecules containing Src homology 2 domains, including PI3K regulatory subunit and Grb2. Subsequently, signaling pathways, such as the PI3K and Ras-MAPK cascades, are activated19–21. Accumulated data indicate that activation of these pathways is required for IGF-I bioactivity. In particular, activated PI3K generates phosphatidylinositol-3,4,5-triphosphate, leading to the activation of Ser/Thr kinase Akt. Activated Akt then activates the mechanistic target of rapamycin complex 1 (mTORC1) via phosphorylation-mediated suppression of the tuberous sclerosis complex protein complex, which inhibits the small GTPase, Rheb, an essential activator of mTORC1. The mTORC1 regulates many activities of IGF-I by phosphorylating distinct substrates, including S6 kinase 1, to regulate protein translation, autophagy, and cell growth.

Furthermore, the downregulation mechanism of the IGF-I signaling pathway has been extensively studied. Some studies have reported that IRS-1, an IRS family protein, is degraded by IGF-I/insulin signaling activation. IRS-1 was degraded via the ubiquitin-mediated 26S proteasome, and this degradation was blocked by the inhibition of phosphatidylinositol 3′-kinase activity22. The protein levels of IRS-1 are also decreased by the downstream kinase, mTORC1. The serine phosphorylation of IRS-1 via active mTORC1 recruits the SCFβ-TRCP E3 ligase complex, catalyzing IRS-1 degradation23. As IRS-1 is an important mediator of IGF-I signaling, it is widely accepted that a decrease in IRS-1 protein levels is one of the mechanism involved in the downregulation of IGF-I signaling. However, recently, we reported a novel function for IRS-1 related to IGF-I signaling desensitization in L6 myoblasts: IRS-1 associates with the medium chain of the clathrin-coated adapter protein, AP2 and competitively inhibits its function. This process suppresses the internalization of active IGF-I receptors on the plasma membrane24. This novel downregulation mechanism does not rely on IRS-1’s role as a signaling mediator but instead reveals a novel function that modulates IGF-I receptor internalization.

Recently, we reported that differences in IRS-1 protein levels induce cell competition during myogenesis in L6 myoblasts. Briefly, cells with high IRS-1 levels are eliminated from the cell layer via cell competition25. Cell competition is a cell fitness-sensing mechanism whereby less fit cells are eliminated as ‘losers’ when surrounded by more fit cells, the ‘winners’26,27. However, the biological significance of cell competition driven by differential expression levels of IRS-1 during myogenic differentiation remains unclear.

In this study, we investigated the detailed mechanisms by which IGF-I determines different cell fates from the aspect of IGF-I signaling dynamics. IGF-I concentration was revealed to be a bifurcation parameter for determining whether the IGF-I signaling oscillates or remains constant. In addition, proliferation was induced when the IGF-I signaling was constant, and differentiation was induced when it oscillated. These results strongly suggest that IGF-I concentration determines cell fate by altering IGF-I signaling dynamics. In addition, IRS-1 oscillations were synchronized via cell competition in a cell-autonomous manner, and this IGF-I signaling synchronization is critical for cell fusion to form multinucleate myotubes.

Results

High concentration of IGF-I inhibited myogenic differentiation but enhanced proliferation

IGF-I is essential for the proliferation and differentiation of L6 myoblasts. Studies have shown that muscle differentiation is inhibited at high IGF-I concentrations15. Thus, we examined proliferation and differentiation abilities in L6 myoblasts at high and low IGF-I concentrations. Confluent L6 myoblasts were differentiated into myotubes by exchanging Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) for DMEM with 2% FBS (differentiation medium) containing 0 or 100 ng/mL IGF-I. Two days after the induction of differentiation, the expression of the myogenic marker protein, MyHC (Myosin Heavy Chain), was induced in the differentiation medium that did not contain IGF-I. However, when 100 ng/mL IGF-I was added to the differentiation medium, MyHC expression was impaired (Fig. 1A), indicating that a high concentration of IGF-I inhibited myogenic differentiation. Expression levels of the myogenic master transcription factor, myogenin, were also impaired after the addition of 100 ng/mL IGF-I on the second day. Furthermore, the fusion index, which indicates the differentiation level of myoblasts into multinucleate myotube cells, was impaired after adding 100 ng/mL IGF-I (Fig. 1B,C). Next, their proliferative abilities under the same conditions were examined. [3H]-labeled thymidine was added to the medium for 4 h, whereafter the [3H] incorporated into DNA was measured as an indicator of proliferation ability. When L6 myoblasts were cultured in DMEM with 2% FBS containing 0, 1, or 10 ng/mL IGF-I, cell proliferation ability was weak. However, cell proliferation was enhanced when cultured in DMEM with 2% FBS containing 100 ng/mL IGF-I (Fig. 1D). Thus, the myoblast cell fate switched in the presence of different concentrations of IGF-I. To investigate the molecular mechanism by which IGF-I concentration switches the cell fate of L6 myoblasts, we analyzed whether the activation dynamics of IGF-I signaling were affected by differences in the IGF-I concentration.Fig. 1 Effects of IGF-I concentration on IGF-I signaling pathway dynamics and bioactivity expression. (A) L6 myoblasts were incubated in a differentiation medium (DMEM with 2% fetal bovine serum (FBS)) supplemented with either 0 or 100 ng/mL insulin-like growth factor-I (IGF-I). Cell lysates were collected at 0, 1, or 2 days post-differentiation induction for immunoblotting analysis using the specified antibody. (B) L6 myoblasts were cultured in a differentiation medium. Cells were fixed with 4% paraformaldehyde at 0 and 4 days post-differentiation induction and subjected to immunostaining analysis using the MyHC antibody. Scale bar = 50 µm. (C) The fusion index was determined (n = 3). Data are presented as mean ± SEM. *P < 0.05, determined by Student’s t-test. (D) L6 myoblasts were cultured in a differentiation medium (DMEM with 2% FBS) supplemented with 0, 1, 10, or 100 ng/mL IGF-I. Forty-four hours later, [methyl-3H] thymidine was added, and after a 4-h incubation, the amount of [3H] incorporated into DNA was measured as an indicator of proliferation ability (n = 6). Data are presented as mean ± SEM. **P < 0.01, analyzed using one-way ANOVA followed by Tukey’s post hoc test.

Mathematical model of IGF-I signaling

We constructed a mathematical model of IGF-I signaling. Recently, we reported a novel regulatory mechanism of the IGF-I signaling pathway in L6 myoblasts. Briefly, (1) IRS-1 interferes with IGF-I receptor internalization through competitively inhibiting AP2 function24. (2) IRS-1 protein levels are downregulated by active mTORC1 kinase23. As IGF-I signaling is known to be downregulated by IGF-I receptor internalization, high IRS-1 levels lead to their sustained activation. Thus, in this model, IRS-1 is not a mediator, but rather a regulator that modulates the duration of IGF-I signaling pathway activity (Fig. 2A).Fig. 2 Mathematical model of the IGF-I signaling pathway. (A) Schematic illustration of the IGF-I signaling pathway model. Insulin receptor substrate-1 (IRS-1) inhibits AP2 function, thereby suppressing internalization of the active IGF-I receptor from the plasma membrane. Downstream signaling pathway activation induces the degradation of IRS-1. In this model, IRS-1 is not a mediator but rather a regulator of the IGF signaling pathway. (B) A mathematical model based on the IGF-I signaling pathway. (C,D) Simulation results of the IGF-I signaling pathway. C: k1 = 0.006. D: k1 = 0.06. (E) L6 myoblasts were serum-starved for 18 h, followed by stimulation with DMEM + 2% FBS containing 1 or 100 ng/mL IGF-I. Cell lysates were prepared from each sample, and the total cell lysate was used for immunoblotting analysis with anti-IRS-1, anti-pAkt, or anti-Akt antibodies. BSA bovine serum albumin, mTORC1 mechanistic target of rapamycin complex 1, PI3K phosphatidylinositol 3-kinase.

We modeled the IGF-I signaling pathways using the form of ordinary differential equations (Fig. 2B):1 dxdt=fx,k,

where x is a vector of substrates and k is a vector of the parameters. The ordinary differential equations for the three variables in the system are given as follows:2 dpIGFIRdt=k1-k2pIGFIR1-IRS1,

3 dIRS1dt=k3-k4IRS1pmTORC1,

4 dpmTORC1dt=k5pIGFIR-k6pmTORC1.

As shown below, the IGF-I signaling system has a unique equilibrium with nonnegative values:5 αγ+βαβ,αγαγ+β,αγ+βαβγ,

where6 α=k2k1,β=k4k3,γ=k6k5.

We performed a linear stability analysis for this equilibrium point. That is, we analytically obtained the Jacobian matrix (J: linearized matrix) at the equilibrium point, and obtained the characteristic polynomial P.7 J=-k21-αγαγ+βk1αγ+ββ00-k3αγ+βαγ-k4αγαγ+βk50-k6,

8 P=λ3+k2βαγ+β+k3αγ+βαγ+k6λ2+αγ+βk2β+αγk3αγ+β+1k6αγλ+αγ+β.

The stability of the equilibrium point is determined by the sign of the real part of the eigenvalues λ of the Jacobian matrix. The eigenvalues are given by the roots of the characteristic equation, P = 0. The equation has one negative real root (λ1) and two complex roots (λ2 and λ3). To examine the stability of the point, Hurwitz’s stability discriminant method was applied to P. The first and second Hurwitz determinants are always positive, and the third Hurwitz determinant given as:9 H3=αγ+β-k2βαγ+β+k3αγ+βαγ+k6αγ+βk2β+αγk3αγ+β+1k6αγ.

When H3 is positive, all roots of P = 0 have a negative real part, i.e., the equilibrium point is stable. By transforming H3, we define our criteria of the stability F.10 F:=αγ+βk2βαγ+β+k3αγ+βαγ+k6αγ+βk2β+αγk3αγ+β+1k6αγ.

Numerical calculations confirmed that at F = 1, signs of the real parts of λ2 and λ3 switch. The equilibrium point is stable if F > 1 but unstable when F ≦1. Therefore, in this system, Hopf bifurcation occurs at F = 1.

As F is a function of k, the stability of the equilibrium switches as k varies (Fig. S1A). Each coefficient of this system was optimized by fitting the experimental results of IRS-1 protein levels and Akt activity (related to pmTORC1 activity) at various time points (0 min, 5 min, 30 min, 60 min, 3 h, 6 h, and 12 h) after stimulation with 100 ng/mL IGF-I (Fig. S2A). For fitting, Bayesian optimization was used. From this optimization process, k1–k6 coefficients, could be set, respectively, as shown in Fig. S2B. A comparison of the numerical calculations with optimized coefficient results with the actual values are shown in Fig. S2C. Evaluating the relationship between the k and F values predicted whether IGF-I signaling would oscillate or remain constant (Fig. S3). The values obtained by substituting the optimized coefficients into the F formula are indicated with a white cross symbol in each graph. Furthermore, we showed the change in the F value when coefficients on both axes were altered. In each graph, the F value is shown in the heatmap. A red color indicates that F > 1. For example, when k1 decreases, F decreases. As k1 is a value that depends on the IGF-I concentration, the IGF-I concentration is a bifurcation parameter that determines whether the IGF-I signaling pathway will oscillate or remain constant. This result can be predicted by referring to the following formula for F: the larger the k1 value, the larger the F value. Considering that F < 1 when k1 = 0, a high IGF-I concentration would stabilize the system with a large F value, whereas a low IGF-I concentration would destabilize the system with a small F value. The simulation results obtained through numerical calculations indicate that IGF-I signaling switches between constant and oscillatory signals depending on k1 (Fig. 2C,D). Interestingly, the simulation results indicate that the IGF-I signaling is constant when the optimized k1 value is used (k1 = 0.060; Fig. 2C). However, when the equivalent k1 value for the IGF-I concentration is set to one-tenth of the amount (k1 = 0.006), IGF-I signaling oscillates (Fig. 2D). As shown in Fig. 2C, the F value is greater than 1, whereas in Fig. 2D, it is less than 1. Bifurcation diagrams showing the relationship between the k1 value and amplitude of IRS-1 protein levels are shown in Fig. S1B.

On the other hand, it is accepted by many researchers that IRS-1 is a critical mediator of the IGF-I signaling pathway and that activation of downstream kinase, mTORC1 leads to proteasomal degradation of IRS-1 resulting in suppression of IGF-I signaling activity. We also modeled this canonical IGF-I signaling pathway as differential equation (Fig. S4). This system has two different equilibria, E+, E−. Equilibrium point E− is unstable but exists in a region with negative [IRS1], [pIRS1], and [pmTORC1] coordinates. Thus, a state that is impossible in biological phenomena can be realized computationally. On the other hand, equilibrium point E+ is proved to be always stable under k > 0. These data strongly indicated that, in this canonical system, IGF-I signaling activity is always constant.

IGF-I signaling dynamics in L6 myoblasts

To evaluate how the IGF-I signaling pathway was activated in cells, immunoblotting analysis was performed on the L6 myoblasts (Fig. 2E). L6 myoblasts were serum-starved for 18 h, followed by stimulation with 1, 10, or 100 ng/mL IGF-I for the indicated periods. The amount of IRS-1 protein, whose levels were altered in response to IGF-I stimulation, was measured. IRS-1 protein levels increased in all groups after 1 h of IGF-I stimulation. In groups stimulated with 1 ng/mL IGF-I, IRS-1 levels gradually increased for up to 18 h, decreased sharply at 24 h, and then recovered at 30 h. In the groups stimulated with 10 ng/mL IGF-I, IRS-1 levels decreased at 6 h, gradually increased again from 18 to 30 h, decreased at 36 h, and increased thrice at 48 h. Contrarily, in the 100 ng/mL IGF-I-stimulated group, IRS-1 levels decreased at 6 h, and little change was observed. These data indicated that the IGF-I signaling oscillated at a concentration of less than 100 ng/mL IGF-I, whereas the addition of 100 ng/mL IGF-I stabilized it. Contrastingly, activation of Akt, which is related to mTORC1 activity, did not oscillate in all test groups. Because prolonged incubation in serum-free medium is a unideal condition for cells, we performed similar experiments using medium containing 2% FBS. L6 myoblasts were serum-starved for 18 h and stimulated with DMEM 2% FBS containing 0, 1, or 100 ng/mL IGF-I. Stimulation with 2% FBS containing 0 or 1 ng/mL IGF-I made IGF signaling oscillate, but 100 ng/mL IGF-I addition did not (Fig. S5A). Moreover, in mouse C2C12 myoblasts, IRS-1 protein levels and phosphorylated Akt levels were oscillated by stimulation with DEME 2% FBS containing IGF-I (Fig. S5B). In addition, nuclear/cytoplasmic localization of FoxO1 in C2C12 cells under the 100 ng/mL IGF-I stimulation condition was oscillated (Fig. S5C). These experiments data strongly suggested that IGF-I signaling can be oscillated in myoblast under some conditions, and that a model in which IRS-1 is a regulator rather than a mediator (Fig. 2A) is more reliable than a canonical model in which IRS-1 is a mediator (Fig. S4).

Cellular automaton simulation predicted that IRS-1 protein levels oscillate in phase through cell competition during myoblast differentiation

We previously reported that differential expression levels of the IRS-1 protein induce cell competition and that high-level IRS-1 cells are selectively eliminated from cell layers when surrounded by low-level IRS-1 cells25. Using cellular automaton analysis, IRS-1 protein levels during the progression of myoblast differentiation were simulated while considering cell competition (Fig. 3A). In this cellular automaton analysis, the cells were shown in a hexagon, and each cell was attached to six other cells. Within each cell, IRS-1 protein levels oscillated in different phases. When the target cell was surrounded by cells with lower levels of IRS-1 (the threshold for the difference in IRS-1 protein levels at which cell competition occurs is set at 0.136; 40% of the amplitude of the oscillation), the target cell was eliminated. The remaining space was then filled by the proliferation of neighboring cells. Detailed conditions under which the cells were eliminated are shown in Fig. 3A. At first, k1 value was fixed at 0.002, which is around the maximum amplitude of IRS-1 protein level oscillation (Fig. S1B). When the threshold for differences in IRS-1 protein levels at which cell competition occurs was varied, it was observed that lower thresholds resulted in the formation of cell populations with aligned IRS-1 levels (Fig. S6A). In the later analysis, IRS-1 level difference threshold is fixed at 0.136 (40% of amplitude of the oscillation), and the k1 value was fixed at 0.002. At time 0, each cell had a different IRS-1 protein level because IRS-1 oscillated at different phases (t = 0; Fig. 3B). Over time, some cell groups whose IRS-1 protein levels are the same are formed (t = 20–140; Fig. 3B). These simulation results indicate that cell competition gradually aligns the IRS-1 levels of neighboring cells, forming cell populations that oscillate during the same phase.Fig. 3 Synchronization of IGF-I signaling oscillations. (A) Cellular automaton-based algorithm considering cell competition. When the target cell is surrounded by low-level IRS-1 cells, target cells are eliminated, and the empty space is replaced by the proliferation of neighboring cells. (B) Cellular automaton simulation results. The IRS-1 level in each cell is shown as a heatmap, and the dead space is in black. At time 0, each cell had different IRS-1 protein levels because IRS-1 oscillation was not synchronized. Over time, IRS-1 protein levels gradually synchronized between neighboring cells. (C) L6 myoblasts were serum-starved for 18 h, followed by stimulation with 100 ng/mL IGF-I for the indicated time. Afterward, cells were fixed and immunostained with anti-IRS-1 antibody. (D) L6 myoblasts were differentiated into myotubes in a differentiation medium. On days 0, 1, or 2 after induction of differentiation, cells were fixed and immunostained with anti-IRS-1 antibody. The green color shows IRS-1, and the blue color indicates the nuclei stained with Hoechst 33342. Scale bar = 20 µm; applicable to all images in each panel. (E) The diversity index was calculated from the data of photographs immunostained with IRS-1 and shown as a graph (n = 4). Results are presented as mean ± SEM. *P < 0.05. One-way ANOVA and Tukey’s post hoc test were performed for assessment.

Immunofluorescent analysis revealed synchronized IRS-1 protein oscillations in differentiated myotubes

To confirm this prediction, IRS-1 protein levels in each cell were assessed using immunostaining with an anti-IRS-1 antibody during the progression of myoblast differentiation. Initially, L6 myoblasts were serum-starved for 18 h, stimulated with 100 ng/mL IGF-1, and stained with an anti-IRS-1 antibody (Fig. 3C). Under serum-starved conditions, the fluorescence level of IRS-1 was high, and IRS-1 was mainly localized in nuclei. One hour after IGF-I stimulation, the fluorescence intensity decreased, and the IRS-1 proteins were localized throughout the cell. IRS-1 proteins were exported from nuclei 6 h later and localized mainly in the cytosol. It has been reported that IRS-1 localization was changed in response to IGF-I, but the underlying mechanism remains unknown. Although the relationship between the difference in IRS-1 localization and oscillations of IRS-1 protein level is unclear, these results show that the status of IGF-I signaling activity can be identified by immunostaining of IRS-1. Thus, three types of IRS-1 staining patterns (Type A, B, and C) were identified (Fig. 3C). L6 myoblasts were differentiated into myotubes by culturing in a differentiation medium. Cells were then immunostained with an anti-IRS-1 antibody at 0, 1, or 2 days after the induction of differentiation (Fig. 3D,E). Before induction of differentiation, the staining pattern of IRS-1 was random. Two days after the induction of differentiation, IRS-1 immunostaining patterns aligned with each other. As mentioned in the “Materials and methods” section, we defined the diversity index as a synchronization parameter and calculated it at 0, 1, and 2 days after the induction of differentiation. Two days after the induction of differentiation, the diversity index decreased significantly, suggesting that the IRS-1 protein oscillation was synchronized after the induction of differentiation.

Synchronization of IGF-I signaling oscillation was critical for myogenic cell fusion to form multinucleate myotubes

To evaluate the biological significance of IGF-I signaling synchronization, cell competition was inhibited by adding an apoptotic inhibitor, Z-VAD-FMK, to the differentiation medium. Addition of Z-VAD-FMK impaired the decrease observed in the diversity index (Fig. 4A), indicating that the synchronization of oscillating IRS-1 levels was inhibited. Z-VAD-FMK addition did not inhibit the expression of MyHC but significantly decreased the fusion index (Fig. 4B). Myomaker plays an important role in myogenic cell fusion28, and the addition of Z-VAD-FMK was found to decrease its mRNA levels (Fig. 4C). These results indicated that apoptotic inhibitors impeded myogenic cell fusion to form multinucleate myotubes.Fig. 4 Synchronization of IRS-1 oscillation is critical for cell fusion. (A) L6 myoblast differentiation was induced in the differentiation medium containing Dimethyl sulfoxide (DMSO) or Z-VAD-FMK. At 0 or 4 days after induction of differentiation, cells were fixed and immunostained with an anti-IRS-1 antibody. The green color shows IRS-1, and the blue color indicates the nuclei stained with Hoechst 33342. Scale bar = 50 µm; applicable to all images in each panel. The diversity index was calculated and shown in the graph (n = 4). Results are presented as mean ± SEM. *P < 0.05. One-way ANOVA and Tukey’s post hoc test were performed for assessment. (B) L6 myoblasts were differentiated in the differentiation medium for 4 days. Cells were fixed and immunostained with an anti-MyHC antibody. Scale bar = 20. The fusion index was calculated and shown in the graphs (n = 3). Results are presented as mean ± SEM. *P < 0.05. Student’s t-test was performed for assessment. (C) L6 myoblasts were differentiated in the differentiation medium for 3 days. Myomaker mRNA levels in L6 myoblasts were measured via qPCR (n = 3). Results are presented as mean ± SEM. *P < 0.05. One-way ANOVA and Tukey’s post hoc test were performed for assessment. (D) L6 myoblasts were directly differentiated by exchanging the culture medium from DMEM + 10% FBS to DMEM + 2% FBS (normal). L6 myoblasts were serum-starved for 1 day, followed by differentiation induction in DMEM + 2% FBS. Total cell lysates were prepared for immunoblotting analysis using the indicated antibodies.

Next, we examined whether synchronization of IGF-I signaling oscillations was sufficient for myogenic differentiation. L6 myoblasts were serum-starved for 1 day to synchronize IGF-I signaling oscillation in advance, whereafter differentiation was induced (Fig. 4D). Serum removal before the induction of differentiation clearly accelerated MyHC expression. Interestingly, caspase-3 activation did not enhance after one day under serum-starved conditions. These data strongly suggested that differentiation was accelerated by the pre-synchronization of IGF-I signaling following serum removal.

Synchronization of IGF-I signaling oscillation possibly occurs only under limited IGF concentrations

The relationship between the k1 value and amplitude of IRS-1 protein oscillation is shown in Figs. S1B and S6B. The k1 value at which the oscillation and stability switch occurred was approximately 0.0077 (Hopf branch [HB]; Fig. S6B). The amplitude of the IRS-1 protein levels was low when k1 was close to the HB. Furthermore, as k1 approached zero, the amplitude of IRS-1 also decreased. Thus, the signaling amplitude was extremely small at IGF-I concentrations near the HB or zero. IGF-I concentrations at which IGF-I signaling oscillated were in the single-digit range, indicating that signaling oscillated only at very limited concentrations. Results of the cellular automaton analysis at various k1 values are shown in Fig. S6B. When the amplitude of the IRS-1 level is large (when k1 is between 0.002 and 0.005; very limited concentrations of IGF-I), the amount of IRS-1 in cells becomes synchronized; however, above or below that amount, no synchronization occurs because of the low amplitude of IRS-1 levels.

Discussion

It is well established that IGF-I is an essential hormone for both myoblast proliferation and differentiation. Here, we focused on the difference in IGF-I signaling dynamics at different IGF-I concentrations. Numerical simulation results indicate that IGF-I signaling oscillates at low concentrations and remains stable at high concentrations. Using data from samples treated with 100 ng/mL IGF-I, a k1 value of 0.067 was calculated to predict approximate IGF-I concentrations. The estimated branching concentration of IGF-I was around 88 ng/mL When k1 was 0.067 (IGF-I concentration 100 ng/mL), signaling was stable; When k1 was 0.0067 (IGF-I concentration 10 ng/mL), oscillations occurred, consistent with numerical and experimental findings. Despite its simplicity, the IGF-I signaling model, which used three variables, produced bifurcation analysis results that were consistent with the experiments. Previous data on IRS-1 knockdown not affecting insulin/IGF signaling pathway activation24,29 and IRS-1 overexpression not enhancing Akt activation could not be reconciled with the previous IRS-1 model as a signaling mediator30. However, our current model suggests IRS-1 acts as a signaling modulator, potentially explaining these conflicting observations.

We have some limitations in our IGF-I signaling mathematical model. Some parameters did not align with the fitting data (Fig. S2C). The duration period of the IGF-I signaling oscillation differs between the numerical simulation results and experimental data. Our model is designed to elucidate qualitative dynamics in IGF-I signaling but not for quantitative optimization. Therefore, the accuracy of the fitting data is low, and there are some errors with the duration period of IGF-I signaling oscillation. This error would be the cause of the inconsistency between the timing of the phase alignment of IRS-1 oscillation in the cell and the timing of phase alignment in the cellular automaton analysis. In addition, numerical simulation results predicted that pAkt is also oscillated. However, oscillation could not be observed in the experimental results in L6 myoblasts. We believe that this discrepancy is due to the weak IGF-I signaling activity, which is below the detection limit in Western blotting in L6 so that oscillations cannot be detected; indeed, oscillations in Akt activation and the localization of Foxo1 could be detected in C2C12 cells which has higher IGF-I signaling activation level than L6 (Fig. S5).

The IGF-I signal transduction pathway is similar to that of insulin. However, we can predict that insulin signaling dynamics are different from those of IGFs. As blood insulin levels are transient in the body, insulin bioactivity is transiently expressed and varies continuously in a concentration-dependent manner31. Contrarily, blood IGF-I is maintained constantly throughout the day because it has long-running bioactivities, including cell proliferation and cell differentiation31. In our study, we showed that the concentration of IGF-I, unlike that of insulin, is a discontinuous switching parameter of signaling dynamics. Data showing that the concentration of IGF-I transformed cell fate and signaling dynamics coincided strongly suggest that IGF signaling dynamics determine cell fate. It is well known that myoblasts can differentiate into myotubes or myofibers by changing culture media from DMEM with 20% or 10% FBS to DMEM with 2% FBS or 5% horse serum14,32. This is thought to be caused by decreased proliferative activity of some growth factors, such as the epidermal growth factor (EGF) and bFGF33,34. However, our report suggested that myoblasts differentiate into myotubes when IGF signaling oscillates after exchanging media from DMEM with 10% FBS to DMEM with 2% FBS; in other words, from a high to a low IGF-I concentration.

IGF-I signaling oscillation is essential for myogenic differentiation as it involves FoxO1 activation. FoxO1, a transcription factor, is excluded from the nucleus and inactivated upon activation of IGF-I signaling35. There are reports that active FoxO1 induces myogenic differentiation and that its inactivation is also necessary35–37. Additionally, we previously reported that IRS-1 overexpression inhibits myogenic differentiation due to continuous FoxO1 exclusion from nuclei30. Sustained FoxO1 inhibition via IGF-I over-addition or IRS-1 overexpression impairs myoblast cell fusion38–40. Thus, IGF-I signaling must be suppressed and activated during myogenic differentiation to allow FoxO1 to activate and enhance the transcription of important myogenic proteins. In this study, we have shown that IRS-1 localized in the nucleus was excluded from the nucleus in response to IGF-I stimulation. Although we have reported that differential expression of IRS-1 protein level induced the cell competition, the present results suggest that difference in the subcellular localization of IRS-1 might induce cell competition. Further studies are required in this respect.

Owing to cell competition, cell populations with synchronized IGF-I signaling may fuse to form multinucleated myotubes. Furthermore, an apoptosis inhibitor significantly inhibited the synchronization of IGF-I signaling and myogenic cell fusion. Pre-synchronization of IGF-I signaling by serum starvation enhanced cell differentiation. These results strongly suggest that the synchronization of IGF-I signaling via cell competition is critical for myogenic cell fusion. Myomaker and myomixer are directly involved in cell fusion. Their expression is regulated by typical muscle-specific transcription factors, such as myoblast determination protein 1 (MyoD) and myogenin, as well as by mechanisms that specifically regulate cell fusion, such as ERK5 activation41,42. Therefore, the synchronization of IGF-I signaling increasing myomaker expression remains unknown and requires further analysis.

Using the F value, it was possible to uncover a bifurcation parameter to determine IGF-I signaling dynamics (Fig. S4). For example, the IRS-1 production parameter, k3, is a bifurcation parameter. IGF-I signaling may be constant when k3 is too high or low. This indicated the possibility that differentiation was inhibited when IRS-1 levels were both too high and low. We have previously reported that IRS-1 overexpression inhibits myogenic differentiation30. Such manipulation of IGF-I signaling dynamics could modulate cell fate by artificially changing the coefficients.

There are reports that the localization or activity of some signaling proteins oscillates and that signaling oscillations play essential roles in bioactivity expression. For example, upon EGF stimulation, sustained oscillation of extracellular signal-regulated kinase (ERK) proteins between the nucleus and cytoplasm has been observed43. This stochastic ERK activity pulse regulates cell proliferation rates in a density-dependent manner44,45. In addition, switch-like ERK activation is essential for invagination of the Drosophila tracheal placode46. Some reports have shown that Akt phosphorylation in mice fed ad libitum resulted in elevated levels of pAkt at nighttime47, when the animals normally ingested food. These feeding rhythms were sufficient to generate cycles of Akt phosphorylation. Moreover, these ultradian Akt activation rhythms were observed in a circadian clock-independent manner47. Single-cell time-lapse imaging and computational modeling of NF-κB localization showed asynchronous oscillation following signaling stimulation, and the transcription of target genes were dependent on NF-κB oscillation48. Thus, the activity and localization of many signaling molecules oscillate; however, regulating signaling dynamics under physiological conditions is unknown. We showed that a slight change in IGF-I concentration controls the oscillations of IGF-I signaling.

This study had some limitations. The IGF-I models created in this study and the validation experiments were mainly performed using L6 myoblasts, and it is unclear whether the dynamics of IGF-I signaling changes in the same manner with IGF-I concentration in different cell lines. Future research must investigate the dynamics of IGF-I signaling in myoblasts via a system that can track IGF-I signaling activity in animal models.

This study concludes that the IGF-I concentration is a bifurcation parameter that determines cell fate by switching IGF-I signaling dynamics. High IGF-I levels inhibited myogenesis owing to constant IGF-I signaling. When the IGF-I level was low, synchronization of IGF-I signaling failed because of the low amplitude of IRS-1 protein levels (Fig. S5). These results indicated that myogenic differentiation was induced only at a limited IGF-I concentration. This system may be an excellent cell-autonomous system in which IGF-I controls the oscillation of IGF-I signaling and the amplitude of IRS-1 level oscillations, ensuring that cells do not easily induce muscle differentiation.

Materials and methods

Materials

DMEM and phosphate-buffered saline (PBS) were purchased from Nissui Pharmaceutical Co. (Tokyo, Japan). FBS was obtained from Sigma-Aldrich (St. Louis, MO, USA), and IGF-I from Wako Chemicals (Tokyo, Japan). Penicillin and streptomycin were obtained from Banyu Pharmaceutical Co. (Tokyo, Japan). Polyclonal anti-IRS-1 antibodies for immunoblotting and immunostaining were obtained from Merck Millipore (Middlesex Country, MA, USA) and ProteinTech (Tokyo, Japan), respectively. Anti-caspase-3 antibody was purchased from Cell Signaling Technology (Danvers, MA, USA), and anti-MyHC antibody from Merck Millipore. Hoechst 33342 was purchased from Molecular Probes (Eugene, OR, USA) and z-VAD-FMK from BD Biosciences (Franklin Lakes, NJ, USA). Horseradish peroxidase-conjugated secondary anti-rabbit and anti-mouse IgG antibodies were obtained from GE Healthcare (Pittsburgh, PA, USA). Enhanced chemiluminescence reagents were obtained from PerkinElmer Life Sciences (Boston, MA, USA). All other chemicals used were of reagent grade and commercially available.

Cell cultures and differentiation

L6 myoblasts were purchased from the American Type Tissue Culture Collection (Manassas, VA, USA). L6 myoblasts were maintained at 37 °C in a humidified, 5% CO2-controlled atmosphere in DMEM supplemented with 10% FBS, 0.1% NaHCO3, 50 IU/mL penicillin, and 50 µg/mL streptomycin. L6 differentiation was induced as described previously30.

Immunoblotting analysis

Cells were lysed at 4 °C with ice-cold lysis buffer (1% NP40, 50 mM Tris–HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 10% glycerol, 20 µg/mL phenylmethylsulfonyl fluoride [PMSF], 5 µg/mL pepstatin, 10 µg/mL leupeptin, 100 KIU/mL aprotinin, 1 mM Na3VO4, and 10 mg/mL p-nitrophenyl phosphate) or ice-cold Ristocetin-induced platelet aggregation (RIPA) buffer (50 mM Tris–HCl [pH 7.4], 15 mM NaCl, 0.1% sodium dodecyl sulfate [SDS], 0.5% deoxycholate, 20 µg/mL PMSF, 5 µg/mL pepstatin, 10 µg/mL leupeptin, 100 KIU/mL aprotinin, 1 mM Na3VO4, and 10 mg/mL p-nitrophenyl phosphate). Insoluble materials were removed via centrifugation at 15,000×g for 10 min at 4 °C, and the supernatant was prepared as the total cell lysate. Immunoblotting was performed as described previously13.

Mathematical model of the IGF signaling pathway

We constructed a mathematical model of the IGF-I signaling pathway, as shown in Fig. 2A,B. Here, we describe the activation of the IGF-I receptor with IGF-I treatment, denoted by [pIGFIR]. The rate at which insulin-like growth factor-I receptor (IGFIR) is activated is:KIGFIR[IGF1](1+KIGFIR)=k1,

where [IGFIR] represents the amount of IGF-I receptors on the plasma membrane, [IGF1] is the concentration of IGF-I in the medium, and K is the coupling constant for IGFIR and IGF-I. We have previously reported that IGF-I receptor levels on the plasma membrane were not altered after IGF-I stimulation24. Therefore, for simplicity, we used the rate at which IGFIR is activated as the constant, k1. This implies that k1 corresponds to the IGF-1 concentration.

Parameter fitting of IGF signaling pathway

Each coefficient of the IGF signaling pathway system was optimized by fitting the experimental results of IRS-1 protein levels and Akt activity (related to pmTORC1 activity). Bayesian optimization was employed to fit the coefficients based on experimentally obtained values. This method utilizes previous experimental outcomes to determine experimental parameters from probability distributions, aiming to identify optimal hyperparameters with minimal trial iterations.

Thymidine incorporation into DNA

L6 cells in 48-well plates were cultured for 24 h in differentiation medium containing the indicated concentrations of IGF-I. [Methyl-3H] thymidine (0.3 μCi/well, 1 μCi/mL; GE Healthcare) was added to each well 4 h before the termination of each experiment. Labeling was terminated by adding 500 µL of 1 M ascorbic acid. The cells were washed twice with ice-cold PBS and twice with ice-cold 10% trichloroacetic acid. Trichloroacetic acid-precipitated materials were solubilized with 250 μL of 0.2 N NaOH and 0.1% SDS, mixed into 5 mL clear-sol II (Nacalai Tesque, Kyoto, Japan), and radioactivity measured with a liquid scintillation counter (Perkin Elmer).

Immunofluorescence staining

For confocal microscopy analysis, L6 cells were grown on coverslips. The cells were fixed for 10 min at 25 °C in prewarmed 4% paraformaldehyde in PBS. After washing three times with PBS, cells were permeabilized with 0.25% Triton X-100 in PBS at 25 °C for 10 min. The cells were washed three times with PBS and then blocked for 1 h at 4 °C with bovine serum albumin (BSA) blocking buffer (3% BSA and 0.025% NaN3 in PBS). Primary antibodies diluted in BSA blocking buffer were added overnight at 4 °C. The samples were washed three times with PBS and incubated for 1 h at 25 °C in a solution of Alexa Fluor-conjugated secondary antibodies diluted in BSA blocking buffer. The coverslips were mounted using Vectashield for visualization under fluorescence (Keyence, Tokyo, Japan) and confocal fluorescence microscopes (Olympus, Tokyo, Japan).

Cellular automaton analysis

Synchronization of IGF-I signaling during myogenic differentiation was simulated using the cellular automaton program. The algorithm used to simulate cell competition is shown in Fig. 3A.

Fusion index

The fusion index was determined by dividing the number of nuclei in myotubes composed of at least three cells by the total number of nuclei observed in each fluorescence micrograph.

Diversity index

L6 myoblasts were induced to differentiate into myotubes. On the indicated days after the induction of differentiation, the cells were immunostained with an anti-IRS-1 antibody. The staining pattern of each cell was classified as A–C, and the number of boundaries (Nb) of all cells in the fluorescence micrographs was counted. If the staining patterns of two neighboring cells differed, 1 was added; if they were the same, 0 was added. This was performed at the boundaries of all cells. The resulting value (Db) was then used to calculate the diversity index with the following formula:Diversityindex=Db2×Nb.

Statistical analysis

All data are defined within the figure legends. Comparisons between two groups were performed using Student’s t-test, whereas comparisons between more than two groups were analyzed via one-way analysis of variance (ANOVA) and Tukey’s post hoc test.

Supplementary Information

Supplementary Figures.

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71739-y.

Acknowledgements

The authors would like to thank Editage (www.Editage.jp) for English language editing. This work was supported in part by the Grants-in-Aid for Scientific Research [Scientific Research (B) #24380152, (B) #15H04583, and (B) #22H02528 to F.H. and Scientific Research (A) #16208028, (A) #22248030, and (S) #25221204 to S.-I.T.]; the Cross-ministerial Moonshot Agriculture, Forestry, and Fisheries Research and Development Program, “Technologies for Smart Bio-industry and Agriculture,” from the Bio-oriented Technology Research Advancement Institution, NARO (Grant Number: 20350956); and the Core-to-Core program from the Japan Society for the Promotion of Science (Grant Number: JPJSCCA20210007 to S.-I.T).

Author contributions

Conceptualization, R.O. and F.H.; Methodology, R.O., K.M., S.O., and F.H.; Software, M.M., K.M., S.W., A.M., and F.H.; Validation, R.O., K.M., S.W., A.M., S.O., and F.H.; Investigation, R.O., K.M., S.W., A.M., and F.H.; Resources, S.N. and Y.Y.; Writing—Original Draft, R.O., K.M., and F.H.; Writing—Review & Editing, R.O., K.M., A.M., T.M., Y.Y., S.T. and F.H.; Funding Acquisition, S.T. and F.H.

Data availability

All relevant data are available from the lead contact, Fumihiko Hakuno (hakuno@g.ecc.u-tokyo.ac.jp), upon request.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Ryosuke Okino, Kazuaki Mukai and Fumihiko Hakuno.
==== Refs
References

1. Nakae J Kido Y Accili D Distinct and overlapping functions of insulin and IGF-I receptors Endocr. Rev. 2001 22 818 835 10.1210/EDRV.22.6.0452 11739335
Nakae, J., Kido, Y. & Accili, D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr. Rev. 22, 818–835. 10.1210/EDRV.22.6.0452 (2001).11739335 10.1210/EDRV.22.6.0452
2. Fukushima T Phosphatidylinositol 3-kinase (PI3K) activity bound to insulin-like growth factor-I (IGF-I) receptor, which is continuously sustained by IGF-I stimulation, is required for IGF-I-induced cell proliferation J. Biol. Chem. 2012 287 29713 29721 10.1074/jbc.M112.393074 22767591
Fukushima, T. et al. Phosphatidylinositol 3-kinase (PI3K) activity bound to insulin-like growth factor-I (IGF-I) receptor, which is continuously sustained by IGF-I stimulation, is required for IGF-I-induced cell proliferation. J. Biol. Chem. 287, 29713–29721. 10.1074/jbc.M112.393074 (2012).22767591 10.1074/jbc.M112.393074
3. Dumont NA Bentzinger CF Sincennes MC Rudnicki MA Satellite cells and skeletal muscle regeneration Compr. Physiol. 2015 5 1027 1059 10.1002/CPHY.C140068 26140708
Dumont, N. A., Bentzinger, C. F., Sincennes, M. C. & Rudnicki, M. A. Satellite cells and skeletal muscle regeneration. Compr. Physiol. 5, 1027–1059. 10.1002/CPHY.C140068 (2015).26140708 10.1002/CPHY.C140068
4. Clemmons DR Role of IGF-I in skeletal muscle mass maintenance Trends Endocrinol. Metab. 2009 20 349 356 10.1016/J.TEM.2009.04.002 19729319
Clemmons, D. R. Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol. Metab. 20, 349–356. 10.1016/J.TEM.2009.04.002 (2009).19729319 10.1016/J.TEM.2009.04.002
5. Barton-Davis ER Shoturma DI Sweeney HL Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle Acta Physiol. Scand. 1999 167 301 305 10.1046/J.1365-201X.1999.00618.X 10632630
Barton-Davis, E. R., Shoturma, D. I. & Sweeney, H. L. Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol. Scand. 167, 301–305. 10.1046/J.1365-201X.1999.00618.X (1999).10632630 10.1046/J.1365-201X.1999.00618.X
6. Edwall D Schalling M Jennische E Norstedt G Induction of insulin-like growth factor I messenger ribonucleic acid during regeneration of rat skeletal muscle Endocrinology 1989 124 820 825 10.1210/ENDO-124-2-820 2912704
Edwall, D., Schalling, M., Jennische, E. & Norstedt, G. Induction of insulin-like growth factor I messenger ribonucleic acid during regeneration of rat skeletal muscle. Endocrinology 124, 820–825. 10.1210/ENDO-124-2-820 (1989).2912704 10.1210/ENDO-124-2-820
7. Coleman ME Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice J. Biol. Chem. 1995 270 12109 12116 10.1074/JBC.270.20.12109 7744859
Coleman, M. E. et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 270, 12109–12116. 10.1074/JBC.270.20.12109 (1995).7744859 10.1074/JBC.270.20.12109
8. Liu JP Baker J Perkins AS Robertson EJ Efstratiadis A Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) Cell 1993 75 59 72 10.1016/S0092-8674(05)80084-4 8402901
Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J. & Efstratiadis, A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75, 59–72. 10.1016/S0092-8674(05)80084-4 (1993).8402901 10.1016/S0092-8674(05)80084-4
9. Florini JR Ewton DZ Magri KA Mangiacapra FJ IGFs and muscle differentiation Adv. Exp. Med. Biol. 1993 343 319 326 10.1007/978-1-4615-2988-0_31 8184742
Florini, J. R., Ewton, D. Z., Magri, K. A. & Mangiacapra, F. J. IGFs and muscle differentiation. Adv. Exp. Med. Biol. 343, 319–326. 10.1007/978-1-4615-2988-0_31 (1993).8184742 10.1007/978-1-4615-2988-0_31
10. Duan C Ren H Gao S Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: Roles in skeletal muscle growth and differentiation Gen. Comp. Endocrinol. 2010 167 344 351 10.1016/J.YGCEN.2010.04.009 20403355
Duan, C., Ren, H. & Gao, S. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: Roles in skeletal muscle growth and differentiation. Gen. Comp. Endocrinol. 167, 344–351. 10.1016/J.YGCEN.2010.04.009 (2010).20403355 10.1016/J.YGCEN.2010.04.009
11. Tollefsen SE Lajara R McCusker RH Clemmons DR Rotwein P Insulin-like growth factors (IGF) in muscle development. Expression of IGF-I, the IGF-I receptor, and an IGF binding protein during myoblast differentiation J. Biol. Chem. 1989 264 13810 13817 10.1016/S0021-9258(18)80073-4 2474537
Tollefsen, S. E., Lajara, R., McCusker, R. H., Clemmons, D. R. & Rotwein, P. Insulin-like growth factors (IGF) in muscle development. Expression of IGF-I, the IGF-I receptor, and an IGF binding protein during myoblast differentiation. J. Biol. Chem. 264, 13810–13817. 10.1016/S0021-9258(18)80073-4 (1989).2474537 10.1016/S0021-9258(18)80073-4
12. Tureckova J Wilson EM Cappalonga JL Rotwein P Insulin-like growth factor-mediated muscle differentiation: Collaboration between phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin J. Biol. Chem. 2001 276 39264 39270 10.1074/jbc.M104991200 11500504
Tureckova, J., Wilson, E. M., Cappalonga, J. L. & Rotwein, P. Insulin-like growth factor-mediated muscle differentiation: Collaboration between phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin. J. Biol. Chem. 276, 39264–39270. 10.1074/jbc.M104991200 (2001).11500504 10.1074/jbc.M104991200
13. Yoneyama Y The AP-1 complex regulates intracellular localization of insulin receptor substrate 1, which is required for insulin-like growth factor I-dependent cell proliferation Mol. Cell. Biol. 2013 33 1991 2003 10.1128/MCB.01394-12 23478262
Yoneyama, Y. et al. The AP-1 complex regulates intracellular localization of insulin receptor substrate 1, which is required for insulin-like growth factor I-dependent cell proliferation. Mol. Cell. Biol. 33, 1991–2003. 10.1128/MCB.01394-12 (2013).23478262 10.1128/MCB.01394-12
14. Florini JR Ewton DZ Coolican SA Growth hormone and the insulin-like growth factor system in myogenesis Endocr. Rev. 1996 17 481 517 10.1210/edrv-17-5-481 8897022
Florini, J. R., Ewton, D. Z. & Coolican, S. A. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr. Rev. 17, 481–517. 10.1210/edrv-17-5-481 (1996).8897022 10.1210/edrv-17-5-481
15. Florini JR Ewton DZ Falen SL Van Wyk JJ Biphasic concentration dependency of stimulation of myoblast differentiation by somatomedins Am. J. Physiol. 1986 250 C771 C778 10.1152/ajpcell.1986.250.5.C771 3518483
Florini, J. R., Ewton, D. Z., Falen, S. L. & Van Wyk, J. J. Biphasic concentration dependency of stimulation of myoblast differentiation by somatomedins. Am. J. Physiol. 250, C771–C778. 10.1152/ajpcell.1986.250.5.C771 (1986).3518483 10.1152/ajpcell.1986.250.5.C771
16. Grønborg M Wulff BS Rasmussen JS Kjeldsen T Gammeltoft S Structure-function relationship of the insulin-like growth factor-I receptor tyrosine kinase J. Biol. Chem. 1993 268 23435 23440 10.1016/S0021-9258(19)49481-7 7693688
Grønborg, M., Wulff, B. S., Rasmussen, J. S., Kjeldsen, T. & Gammeltoft, S. Structure-function relationship of the insulin-like growth factor-I receptor tyrosine kinase. J. Biol. Chem. 268, 23435–23440. 10.1016/S0021-9258(19)49481-7 (1993).7693688 10.1016/S0021-9258(19)49481-7
17. Ullrich A Schlessinger J Signal transduction by receptors with tyrosine kinase activity Cell 1990 61 203 212 10.1016/0092-8674(90)90801-k 2158859
Ullrich, A. & Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203–212. 10.1016/0092-8674(90)90801-k (1990).2158859 10.1016/0092-8674(90)90801-k
18. Yenush L White MF The IRS-signalling system during insulin and cytokine action BioEssays 1997 19 491 500 10.1002/bies.950190608 9204766
Yenush, L. & White, M. F. The IRS-signalling system during insulin and cytokine action. BioEssays 19, 491–500. 10.1002/bies.950190608 (1997).9204766 10.1002/bies.950190608
19. Backer JM Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation EMBO J. 1992 11 3469 3479 10.1002/j.1460-2075.1992.tb05426.x 1380456
Backer, J. M. et al. Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J. 11, 3469–3479. 10.1002/j.1460-2075.1992.tb05426.x (1992).1380456 10.1002/j.1460-2075.1992.tb05426.x
20. Myers MG IRS-1 activates phosphatidylinositol 3′-kinase by associating with Src homology 2 domains of p85 Proc. Natl Acad. Sci. U.S.A. 1992 89 10350 10354 10.1073/pnas.89.21.10350 1332046
Myers, M. G. et al. IRS-1 activates phosphatidylinositol 3′-kinase by associating with Src homology 2 domains of p85. Proc. Natl Acad. Sci. U.S.A. 89, 10350–10354. 10.1073/pnas.89.21.10350 (1992).1332046 10.1073/pnas.89.21.10350
21. Dummler B Hemmings BA Physiological roles of PKB/Akt isoforms in development and disease Biochem. Soc. Trans. 2007 35 231 235 10.1042/BST0350231 17371246
Dummler, B. & Hemmings, B. A. Physiological roles of PKB/Akt isoforms in development and disease. Biochem. Soc. Trans. 35, 231–235. 10.1042/BST0350231 (2007).17371246 10.1042/BST0350231
22. Lee AV Gooch JL Oesterreich S Guler RL Yee D Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3′-kinase inhibition Mol. Cell. Biol. 2000 20 1489 1496 10.1128/MCB.20.5.1489-1496.2000 10669726
Lee, A. V., Gooch, J. L., Oesterreich, S., Guler, R. L. & Yee, D. Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3′-kinase inhibition. Mol. Cell. Biol. 20, 1489–1496. 10.1128/MCB.20.5.1489-1496.2000 (2000).10669726 10.1128/MCB.20.5.1489-1496.2000
23. Yoneyama Y Serine phosphorylation by mTORC1 promotes IRS-1 degradation through SCFβ-TRCP E3 ubiquitin ligase iScience 2018 5 1 18 10.1016/j.isci.2018.06.006 30240640
Yoneyama, Y. et al. Serine phosphorylation by mTORC1 promotes IRS-1 degradation through SCFβ-TRCP E3 ubiquitin ligase. iScience 5, 1–18. 10.1016/j.isci.2018.06.006 (2018).30240640 10.1016/j.isci.2018.06.006
24. Yoneyama Y IRS-1 acts as an endocytic regulator of IGF-I receptor to facilitate sustained IGF signaling ELife 2018 7 893 10.7554/eLife.32893
Yoneyama, Y. et al. IRS-1 acts as an endocytic regulator of IGF-I receptor to facilitate sustained IGF signaling. ELife 7, 893. 10.7554/eLife.32893 (2018).10.7554/eLife.32893
25. Okino R Usui A Yoneyama Y Takahashi SI Hakuno F Myoblasts with higher IRS-1 levels are eliminated from the normal cell layer during differentiation Front. Endocrinol. 2020 11 96 10.3389/fendo.2020.00096
Okino, R., Usui, A., Yoneyama, Y., Takahashi, S. I. & Hakuno, F. Myoblasts with higher IRS-1 levels are eliminated from the normal cell layer during differentiation. Front. Endocrinol. 11, 96. 10.3389/fendo.2020.00096 (2020).10.3389/fendo.2020.00096
26. Simpson P Morata G Differential mitotic rates and patterns of growth in compartments in the Drosophila wing Dev. Biol. 1981 85 299 308 10.1016/0012-1606(81)90261-x 7262460
Simpson, P. & Morata, G. Differential mitotic rates and patterns of growth in compartments in the Drosophila wing. Dev. Biol. 85, 299–308. 10.1016/0012-1606(81)90261-x (1981).7262460 10.1016/0012-1606(81)90261-x
27. Morata G Cell competition: A historical perspective Dev. Biol. 2021 476 33 40 10.1016/J.YDBIO.2021.02.012 33775694
Morata, G. Cell competition: A historical perspective. Dev. Biol. 476, 33–40. 10.1016/J.YDBIO.2021.02.012 (2021).33775694 10.1016/J.YDBIO.2021.02.012
28. Leikina E Myomaker and Myomerger work independently to control distinct steps of membrane remodeling during myoblast fusion Dev. Cell 2018 46 767 780 10.1016/J.DEVCEL.2018.08.006 30197239
Leikina, E. et al. Myomaker and Myomerger work independently to control distinct steps of membrane remodeling during myoblast fusion. Dev. Cell 46, 767–780. 10.1016/J.DEVCEL.2018.08.006 (2018).30197239 10.1016/J.DEVCEL.2018.08.006
29. Sasaki-Suzuki N Growth hormone inhibition of glucose uptake in adipocytes occurs without affecting GLUT4 translocation through an insulin receptor substrate-2-phosphatidylinositol 3-kinase-dependent pathway J. Biol. Chem. 2009 284 6061 6070 10.1074/jbc.M808282200 19122000
Sasaki-Suzuki, N. et al. Growth hormone inhibition of glucose uptake in adipocytes occurs without affecting GLUT4 translocation through an insulin receptor substrate-2-phosphatidylinositol 3-kinase-dependent pathway. J. Biol. Chem. 284, 6061–6070. 10.1074/jbc.M808282200 (2009).19122000 10.1074/jbc.M808282200
30. Hakuno F Constitutive expression of insulin receptor substrate (IRS)-1 inhibits myogenic differentiation through nuclear exclusion of FoxO1 in L6 myoblasts PLoS ONE 2011 6 e25655 10.1371/journal.pone.0025655 21991327
Hakuno, F. et al. Constitutive expression of insulin receptor substrate (IRS)-1 inhibits myogenic differentiation through nuclear exclusion of FoxO1 in L6 myoblasts. PLoS ONE 6, e25655. 10.1371/journal.pone.0025655 (2011).21991327 10.1371/journal.pone.0025655
31. Hakuno F Takahashi SI IGF1 receptor signaling pathways J. Mol. Endocrinol. 2018 61 T69 T86 10.1530/JME-17-0311 29535161
Hakuno, F. & Takahashi, S. I. IGF1 receptor signaling pathways. J. Mol. Endocrinol. 61, T69–T86. 10.1530/JME-17-0311 (2018).29535161 10.1530/JME-17-0311
32. Florini JR ‘Spontaneous’ differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II J. Biol. Chem. 1991 266 15917 15923 10.1016/S0021-9258(18)98496-6 1651927
Florini, J. R. et al. ‘Spontaneous’ differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. J. Biol. Chem. 266, 15917–15923. 10.1016/S0021-9258(18)98496-6 (1991).1651927 10.1016/S0021-9258(18)98496-6
33. Leroy MC Perroud J Darbellay B Bernheim L Konig S Epidermal growth factor receptor down-regulation triggers human myoblast differentiation PLoS ONE 2013 8 e71770 10.1371/JOURNAL.PONE.0071770 23967242
Leroy, M. C., Perroud, J., Darbellay, B., Bernheim, L. & Konig, S. Epidermal growth factor receptor down-regulation triggers human myoblast differentiation. PLoS ONE 8, e71770. 10.1371/JOURNAL.PONE.0071770 (2013).23967242 10.1371/JOURNAL.PONE.0071770
34. Riuzzi F Sorci G Donato R S100B protein regulates myoblast proliferation and differentiation by activating FGFR1 in a bFGF-dependent manner J. Cell Sci. 2011 124 2389 2400 10.1242/JCS.084491 21693575
Riuzzi, F., Sorci, G. & Donato, R. S100B protein regulates myoblast proliferation and differentiation by activating FGFR1 in a bFGF-dependent manner. J. Cell Sci. 124, 2389–2400. 10.1242/JCS.084491 (2011).21693575 10.1242/JCS.084491
35. Hribal ML Nakae J Kitamura T Shutter JR Accili D Regulation of insulin-like growth factor-dependent myoblast differentiation by foxo forkhead transcription factors J. Cell Biol. 2003 162 535 541 10.1083/jcb.200212107 12925703
Hribal, M. L., Nakae, J., Kitamura, T., Shutter, J. R. & Accili, D. Regulation of insulin-like growth factor-dependent myoblast differentiation by foxo forkhead transcription factors. J. Cell Biol. 162, 535–541. 10.1083/jcb.200212107 (2003).12925703 10.1083/jcb.200212107
36. Wu AL Kim JH Zhang C Unterman TG Chen J Forkhead box protein O1 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of rapamycin pathway components Endocrinology 2008 149 1407 1414 10.1210/EN.2007-1470 18079193
Wu, A. L., Kim, J. H., Zhang, C., Unterman, T. G. & Chen, J. Forkhead box protein O1 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of rapamycin pathway components. Endocrinology 149, 1407–1414. 10.1210/EN.2007-1470 (2008).18079193 10.1210/EN.2007-1470
37. Kitamura T A Foxo/Notch pathway controls myogenic differentiation and fiber type specification J. Clin. Investig. 2007 117 2477 2485 10.1172/JCI32054 17717603
Kitamura, T. et al. A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. J. Clin. Investig. 117, 2477–2485. 10.1172/JCI32054 (2007).17717603 10.1172/JCI32054
38. Bois PRJ Grosveld GC FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts EMBO J. 2003 22 1147 1157 10.1093/EMBOJ/CDG116 12606579
Bois, P. R. J. & Grosveld, G. C. FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts. EMBO J. 22, 1147–1157. 10.1093/EMBOJ/CDG116 (2003).12606579 10.1093/EMBOJ/CDG116
39. Nishiyama T Kii I Kudo A Inactivation of rho/ROCK signaling is crucial for the nuclear accumulation of FKHR and myoblast fusion J. Biol. Chem. 2004 279 47311 47319 10.1074/jbc.M403546200 15322110
Nishiyama, T., Kii, I. & Kudo, A. Inactivation of rho/ROCK signaling is crucial for the nuclear accumulation of FKHR and myoblast fusion. J. Biol. Chem. 279, 47311–47319. 10.1074/jbc.M403546200 (2004).15322110 10.1074/jbc.M403546200
40. Xu M Chen X Chen D Yu B Huang Z FoxO1: A novel insight into its molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type specification Oncotarget 2017 8 10662 10674 10.18632/ONCOTARGET.12891 27793012
Xu, M., Chen, X., Chen, D., Yu, B. & Huang, Z. FoxO1: A novel insight into its molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type specification. Oncotarget 8, 10662–10674. 10.18632/ONCOTARGET.12891 (2017).27793012 10.18632/ONCOTARGET.12891
41. Luo W Li E Nie Q Zhang X Myomaker, regulated by MYOD, MYOG and miR-140-3p, promotes chicken myoblast fusion Int. J. Mol. Sci. 2015 16 26186 26201 10.3390/ijms161125946 26540045
Luo, W., Li, E., Nie, Q. & Zhang, X. Myomaker, regulated by MYOD, MYOG and miR-140-3p, promotes chicken myoblast fusion. Int. J. Mol. Sci. 16, 26186–26201. 10.3390/ijms161125946 (2015).26540045 10.3390/ijms161125946
42. Sunadome K ERK5 regulates muscle cell fusion through Klf transcription factors Dev. Cell 2011 20 192 205 10.1016/J.DEVCEL.2010.12.005 21316587
Sunadome, K. et al. ERK5 regulates muscle cell fusion through Klf transcription factors. Dev. Cell 20, 192–205. 10.1016/J.DEVCEL.2010.12.005 (2011).21316587 10.1016/J.DEVCEL.2010.12.005
43. Shankaran H Rapid and sustained nuclear–cytoplasmic ERK oscillations induced by epidermal growth factor Mol. Syst. Biol. 2009 5 332 332 10.1038/MSB.2009.90 19953086
Shankaran, H. et al. Rapid and sustained nuclear–cytoplasmic ERK oscillations induced by epidermal growth factor. Mol. Syst. Biol. 5, 332–332. 10.1038/MSB.2009.90 (2009).19953086 10.1038/MSB.2009.90
44. Yang JM Integrating chemical and mechanical signals through dynamic coupling between cellular protrusions and pulsed ERK activation Nat. Commun. 2018 9 4673 10.1038/s41467-018-07150-9 30405112
Yang, J. M. et al. Integrating chemical and mechanical signals through dynamic coupling between cellular protrusions and pulsed ERK activation. Nat. Commun. 9, 4673. 10.1038/s41467-018-07150-9 (2018).30405112 10.1038/s41467-018-07150-9
45. Aoki K Stochastic ERK activation induced by noise and cell-to-cell propagation regulates cell density-dependent proliferation Mol. Cell 2013 52 529 540 10.1016/J.MOLCEL.2013.09.015 24140422
Aoki, K. et al. Stochastic ERK activation induced by noise and cell-to-cell propagation regulates cell density-dependent proliferation. Mol. Cell 52, 529–540. 10.1016/J.MOLCEL.2013.09.015 (2013).24140422 10.1016/J.MOLCEL.2013.09.015
46. Ogura Y Wen FL Sami MM Shibata T Hayashi S A switch-like activation relay of EGFR-ERK signaling regulates a wave of cellular contractility for epithelial invagination Dev. Cell 2018 46 162 172 10.1016/J.DEVCEL.2018.06.004 29983336
Ogura, Y., Wen, F. L., Sami, M. M., Shibata, T. & Hayashi, S. A switch-like activation relay of EGFR-ERK signaling regulates a wave of cellular contractility for epithelial invagination. Dev. Cell 46, 162–172. 10.1016/J.DEVCEL.2018.06.004 (2018).29983336 10.1016/J.DEVCEL.2018.06.004
47. Vollmers C Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression Proc. Natl. Acad. Sci. U.S.A. 2009 106 21453 21458 10.1073/PNAS.0909591106 19940241
Vollmers, C. et al. Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. Proc. Natl. Acad. Sci. U.S.A. 106, 21453–21458. 10.1073/PNAS.0909591106 (2009).19940241 10.1073/PNAS.0909591106
48. Nelson DE Oscillations in NF-kappaB signaling control the dynamics of gene expression Science 2004 306 704 708 10.1126/science.1099962 15499023
Nelson, D. E. et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 306, 704–708. 10.1126/science.1099962 (2004).15499023 10.1126/science.1099962
